Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer

Kim,Nam Hee; Sung,Hye Youn; Choi,Eun Nam; Lyu,Dahyun; Choi,Hyuck Jae; Ju,Woong; Ahn,Jung-Hyuck

doi:10.3892/or.2014.3110

Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer

Authors:
- Nam Hee Kim
- Hye Youn Sung
- Eun Nam Choi
- Dahyun Lyu
- Hyuck Jae Choi
- Woong Ju
- Jung-Hyuck Ahn
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, School of Medicine, Ewha Womans University, Yangcheon‑ku, Seoul 158-710, Republic of Korea, Department of Biochemistry, School of Medicine, Ewha Womans University, Yangcheon‑ku, Seoul 158-710, Republic of Korea, Department of Radiology and Research, Institute of Radiology, University of Ulsan, College of Medicine, Asan Medical Center, Songpa-ku, Seoul 138-736, Republic of Korea
Published online on: March 24, 2014 https://doi.org/10.3892/or.2014.3110
Pages: 2139-2146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A lack of reliable biomarkers for the early detection and risk of metastatic recurrences makes ovarian cancer the most lethal gynecological cancer. To understand the molecular mechanisms involved in ovarian cancer metastasis in vivo, we analyzed the transcriptional expression pattern in metastatic implants of human ovarian carcinoma xenografts in mice. The expression of 937 genes was significantly different, by at least 2-fold, in the xenografts compared with that in SK-OV-3 cells. We investigated the mechanisms that regulate the expression of one of the profoundly upregulated genes, interferon-induced transmembrane protein 1 (IFITM1), in the metastatic implants. Specific CpG sites within the IFITM1 promoter were hypomethylated in the metastatic implants relative to those in the wild-type SK-OV-3 cells. Treating wild-type SK-OV-3 cells with the demethylating agent 5-aza-2'-deoxycytidine enhanced IFITM1 expression in a dose-dependent manner, implying transcriptional regulation by promoter methylation. We also found that IFITM1 overexpression caused increased migration and invasiveness in SK-OV-3 cells. Our results demonstrate that IFITM1 could be a novel metastasis-promoting gene that enhances the metastatic phenotype in ovarian cancer via epigenetic transcriptional regulation. Our findings also suggest that the status of DNA methylation within the IFITM1 promoter region could be a biomarker indicating metastatic progression in ovarian cancer.

View Figures

View References

1	Ozols RF: Update on the management of ovarian cancer. Cancer J. 8(Suppl 1): S22–S30. 2002.PubMed/NCBI
2	Tummala MK and McGuire WP: Recurrent ovarian cancer. Clin Clin Adv Hematol Oncol. 3:723–736. 2005.
3	Šale S and Orsulic S: Models of ovarian cancer metastasis: murine models. Drug Discov Today Dis Models. 3:149–154. 2006.
4	Sallinen H, Anttila M, Narvainen J, et al: A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol. 103:315–320. 2006. View Article : Google Scholar : PubMed/NCBI
5	Hamilton TC, Young RC, Louie KG, et al: Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44:5286–5290. 1984.PubMed/NCBI
6	Molpus KL, Koelliker D, Atkins L, et al: Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer. 68:588–595. 1996. View Article : Google Scholar : PubMed/NCBI
7	Takahashi S, Doss C, Levy S and Levy R: TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol. 145:2207–2213. 1990.PubMed/NCBI
8	Bradbury LE, Kansas GS, Levy S, Evans RL and Tedder TF: The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol. 149:2841–2850. 1992.PubMed/NCBI
9	Matsumoto AK 1, Martin DR, Carter RH, Klickstein LB, Ahearn JM and Fearon DT: Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med. 178:1407–1417. 1993. View Article : Google Scholar : PubMed/NCBI
10	Brass AL, Huang IC, Benita Y, et al: The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 139:1243–1254. 2009. View Article : Google Scholar : PubMed/NCBI
11	Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:32004.PubMed/NCBI
12	Watts GS, Futscher BW, Holtan N, DeGeest K, Domann FE and Rose SL: DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics. 1:472008. View Article : Google Scholar : PubMed/NCBI
13	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
14	Yu F, Ng SS, Chow BK, et al: Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol. 103:187–195. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yang Y, Lee JH, Kim KY, et al: The interferon-inducible 9–27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett. 221:191–200. 2005.
16	Lee J, Goh SH, Song N, et al: Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. Am J Pathol. 181:43–52. 2012. View Article : Google Scholar : PubMed/NCBI
17	Hatano H, Kudo Y, Ogawa I, et al: IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res. 14:6097–6105. 2008. View Article : Google Scholar : PubMed/NCBI
18	Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Stat Method). 57:289–300. 1995.
19	Naora H and Montell DJ: Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 5:355–366. 2005. View Article : Google Scholar : PubMed/NCBI
20	Howe A, Aplin AE, Alahari SK and Juliano RL: Integrin signaling and cell growth control. Curr Opin Cell Biol. 10:220–231. 1998. View Article : Google Scholar : PubMed/NCBI
21	Aplin A, Howe A, Alahari S and Juliano RL: Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev. 50:197–263. 1998.PubMed/NCBI
22	Choi YP, Kim BG, Gao MQ, Kang S and Cho NH: Targeting ILK and β4 integrin abrogates the invasive potential of ovarian cancer. Biochem Biophys Res Commun. 427:642–648. 2012.
23	Cheon DJ, Tong Y, Sim MS, et al: A collagen-remodeling gene signature regulated by TGFβ signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 20:711–723. 2014.PubMed/NCBI
24	Scotton CJ, Wilson JL, Milliken D, Stamp G and Balkwill FR: Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61:4961–4965. 2001.PubMed/NCBI
25	Salama I 1, Malone PS, Mihaimeed F and Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol. 34:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
26	Davies BR, O’Donnell M, Durkan GC, et al: Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol. 196:292–299. 2002. View Article : Google Scholar : PubMed/NCBI
27	Rudland PS, Platt-Higgins A, Renshaw C, et al: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res. 60:1595–1603. 2000.PubMed/NCBI
28	Ninomiya I, Ohta T, Fushida S, et al: Increased expression of S100A4 and its prognostic significance in esophageal squamous cell carcinoma. Int J Oncol. 18:715–720. 2001.PubMed/NCBI
29	Ai KX, Lu LY, Huang XY, Chen W and Zhang HZ: Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol. 14:1931–1935. 2008. View Article : Google Scholar : PubMed/NCBI
30	Gongoll S, Peters G, Mengel M, et al: Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology. 123:1478–1484. 2002. View Article : Google Scholar : PubMed/NCBI
31	He JD 1, Luo HL, Li J, Feng WT and Chen LB: Influences of the interferon induced transmembrane protein 1 on the proliferation, invasion, and metastasis of the colorectal cancer SW480 cell lines. Chin Med J. 125:517–522. 2012.PubMed/NCBI